Bio-Link and ACROBiosystems Forge Strategic Partnership for AI-Driven Protein Ligand Development

On August 10, Bio-Link Biological Applied Technologies (Shanghai) Co., Ltd. (“Bio-Link”) and ACROBiosystems Co., Ltd. (“ACROBiosystems”) officially held a strategic partnership signing ceremony. Bio-Link Founder and Chairman Zhi Chen, Vice President Tianyong Zhang, and other representatives; as well as ACROBiosystems Founder, Chairman and CEO Yiding Chen, Chief Operating Officer Jingyun Miao, and other representatives attended the ceremony.

The two parties will establish a long-term strategic partnership focused on the development of AI-enabled next-generation affinity purification ligands and affinity chromatography resins, jointly creating next-generation affinity purification solutions integrating “upstream AI-driven proteins + downstream affinity resins.”

Affinity purification is one of the most critical core processes in the production of antibodies and biopharmaceuticals. Its technological advancement directly impacts manufacturing efficiency, product quality, and production costs. With the rapid advancement of artificial intelligence (AI), AI is profoundly reshaping life science tools and the bioprocessing industry, driving new breakthroughs in the design and development of next-generation affinity ligands while creating broad opportunities for collaborative innovation across the entire industry chain.

Figure 1: Bio-Link Founder and Chairman Zhi Chen (right)

and ACROBiosystems Founder, Chairman and CEO Yiding Chen

jointly signing the strategic partnership agreement

Bio-Link is a high-tech enterprise providing integrated process solutions for the life sciences industry, with a long-term focus on the research, development, and manufacturing of critical bioprocess equipment and consumables for biopharmaceutical applications. Since its establishment, Bio-Link has remained committed to the field of chromatography purification, developing proprietary chromatography resin technologies and an intelligent manufacturing system. The company has built comprehensive capabilities covering material development, resin R&D, large-scale manufacturing, quality control, and process application support, providing global biopharmaceutical customers with high-performance purification products and downstream process solutions.

ACROBiosystems is a global biotechnology company dedicated to providing critical biological reagents, solutions, and innovative business models for the global biopharmaceutical and healthcare industries. In recent years, the company has continuously advanced AI-driven protein engineering and affinity ligand development, establishing proprietary VHH affinity ligand development and AI-enabled affinity ligand optimization platforms. These platforms enable the development of next-generation affinity ligands featuring alkaline stability, high coupling capacity, and protease resistance, providing innovative purification solutions for antibodies and antibody fragments.

During the ceremony, representatives from both parties delivered speeches.

In his remarks, Yiding Chen, Founder, Chairman and CEO of ACROBiosystems, stated:

“AI represents a major trend in today’s biopharmaceutical industry, and we must transform challenges brought by change into new opportunities. Building on our strengths in AI-driven protein technologies, together with Bio-Link’s deep technical expertise and strong commercialization capabilities in downstream bioprocess purification, the integration of our complementary strengths and the establishment of this partnership represent a natural outcome of industry development. We believe that through resource sharing and deep collaboration, we can jointly explore new business models, deliver more efficient and cost-effective integrated solutions for the industry, and drive the upgrading and advancement of the entire biopharmaceutical value chain.”

Figure 2: Yiding Chen, Founder, Chairman and CEO of ACROBiosystems,

delivering a speech at the ceremony

Zhi Chen, Founder and Chairman of Bio-Link, stated:

“Affinity purification is one of the most critical core technologies in downstream bioprocessing and represents an important direction for driving cost reduction and efficiency improvement across the industry. ACROBiosystems has established leading advantages in AI-driven affinity ligand development, while Bio-Link has been deeply engaged in chromatography purification processes and industrial-scale manufacturing for many years. This collaboration represents not only the integration of our respective technological capabilities, but also the deep fusion of R&D innovation and commercialization capabilities. Looking ahead, we hope to jointly develop higher-performance and more globally competitive affinity purification solutions, accelerate the transition of innovative achievements into industrial applications, and create greater value for biopharmaceutical customers worldwide.”

Figure 3: Zhi Chen, Founder and Chairman of Bio-Link,

delivering a speech at the ceremony

Based on the shared understanding of industry development trends, the two parties will establish a long-term collaboration mechanism across multiple areas, including next-generation affinity ligand development, joint R&D of affinity resins, AI-enabled customized ligand development, joint product evaluation, technology licensing, and joint marketing initiatives. Together, they will accelerate the translation of innovative achievements into practical applications and provide higher-performance and more reliable integrated solutions for antibody and antibody fragment manufacturing. The two parties will continue to advance breakthroughs in key technologies and industrial applications centered around “AI-enabled next-generation affinity purification technologies.

Figures 4 & 5: Centered on the theme of “Empowering Innovation with AI, Creating the Future through Intelligence,”  Bio-Link and ACROBiosystems will jointly develop next-generation affinity purification solutions integrating “upstream AI-driven proteins + downstream affinity resins.”

In recent years, Bio-Link has continued to strengthen its product and solution capabilities around critical bioprocess steps, further expanding its R&D, manufacturing, and application capabilities in the field of chromatography purification. The company has continuously enhanced its proprietary chromatography resin development and intelligent manufacturing capabilities, establishing a comprehensive capability system spanning material development, product manufacturing, and process application support. Meanwhile, Bio-Link continues to expand into new product and technology areas, including polymer chromatography resins, to better address the demand for high-performance and highly stable products in downstream purification processes for antibodies, recombinant proteins, vaccines, and other biologics.

Bio-Link

Bio-Link Biological Applied Technologies (Shanghai) Co., Ltd. (“Bio-Link”) is a group of technology-driven businesses that provide process solutions in the life sciences industry. The company focuses on the development and production of the key processing equipment and consumables used in the manufacturing process of recombinant protein drugs, vaccines, antibodies, cell therapies, gene therapies, and other biological products. Bio-Link's portfolio of offerings covers the entire upstream and downstream bioprocess such as cell culture, single-use mixing and storage, chromatography, filtration (ultrafiltration/diafiltration, clarification, and virus removal), and hydration products, as well as process development services.

Bio-Link has established sales and service centers in Beijing, Shanghai, Guangzhou, Chengdu, Suzhou, Wuhan, Jinan, Changchun, and other locations, as well as an R&D and application center in Suzhou. In addition, Bio-Link has established subsidiaries in Germany and Singapore to support its global business expansion strategy.

Bio-Link is committed to providing customers with high-quality, innovative products and solutions and strives to build an efficient, safe and competitive biopharmaceutical supply chain eco-system — Link to Enable Biotechnologies.

ACROBiosystems Group

ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and healthcare industries by providing innovative products and business models. The company spans across the globe and maintains offices, R&D centers, and production bases in more than 15 different cities within the United States, Switzerland, the United Kingdom and Germany. ACROBiosystems Group has established numerous long-term and stable partnerships with the world’s top pharmaceutical enterprises, including Pfizer, Novartis, and Johnson & Johnson, and numerous well-known academic institutes. The company comprises several subsidiaries such as ACROBiosystems, bioSeedin, Condense Capital, and ACRODiagnostics.

ACROBiosystems’ brands include Resilient Supply, CytoPak, SAFENSURE, FLAG, Star Staining, Aneuro, ComboX, GENPower and many others. Its main products and services are recombinant proteins, kits, antibodies, scientific services, and other related products. ACROBiosystems employs a strict quality control system for its products that are used in biopharmaceutical research and development, production, and clinical application. This includes targeted discovery and validation, candidate drug screening/optimization, CMC development and pilot production, preclinical research, clinical trials, commercial production, and clinical application of companion diagnostics.

Through the continuous development of new technologies and products, ACROBiosystems Group creates value for the global pharmaceutical industry and actively empowers our partners. The company is dedicated to accelerating the drug development process, including targeted therapies, immunotherapeutic drugs, and their clinical applications, and contributes to global health.